Introduction
Alterations in the expression of the erbB tyrosine kinase receptors are commonly found in cells and tissues derived from numerous human solid tumors, including lung cancer. Among the members of the erbB family, overexpression of erbB-2 occurs in approximately 40% of non-small cell lung carcinoma (NSCLC) and has been associated with poor prognosis (Schneider et al., 1989; Kern et al., 1990; Shi et al., 1992; Smit et al., 1996) . Studies using NSCLC cell lines have shown a positive correlation between the level of erbB-2 expression and enhanced cellular resistance to anticancer drugs such as cisplatin (Tsai et al., 1993 (Tsai et al., , 1995 Paterson et al., 1996) . Similar results have been reported in breast and ovarian adenocarcinoma cells (Benz et al., 1993; Arteaga et al., 1994; Pietras et al., 1994) . Overexpression of erbB-2 in normal human bronchial cells (Noguchi et al., 1993) and transgenic mice (Suda et al., 1990) leads to cell transformation and lung cancer development, respectively. Although the molecular mechanisms by which erbB-2 overexpression contributes to lung carcinogenesis and poor prognosis are not fully understood, there is evidence that this may be mediated by altered signaling pathway(s) coupled to the erbB receptors. For example, overexpression of erbB-2 enhances the anity of heregulin binding to erbB-3 and erbB-4, and favors the activation of epidermal growth factor receptor (EGFR), erbB-3, and erbB-4 through heterodimerization with the erbB-2 receptor (Goldman et al., 1990; Carraway and Cantly, 1994; Karunagaran et al., 1995; Earp, 1995; Graus-Porta et al., 1995; Pinkas-Kramarski et al., 1996a,b; Lewis et al., 1996) ; overexpression of erbB-2 leads to a prolonged activation of mitogen activated protein kinases (MAPK) and stress activated protein kinases (SAPK) (Hynes and Stern, 1994; Karunagaran et al., 1996) ; and erbB-2 cooperates with the other members of erbB family for cell transformation (Di Fiore et al., 1987; Kokai et al., 1989; Wada et al., 1990; Alimandi et al., 1995) . Therefore, selective modulation of erbB signaling pathways has emerged as a potential therapeutic target in cancer. Indeed, strategies to inhibit erbB receptors using antagonists (Arteaga et al., 1994; Pietras et al., 1994; Deshane et al., 1996) , antisense (Vaughn et al., 1995) , or synthetic inhibitors (Fry et al., 1994; Miller et al., 1994; Zhang and Hung, 1996) have proven ecacy in experimental models, and many of these approaches are currently under clinical trials. Immunological approaches using erbB-2 antagonists have shown that erbB signaling regulates a number of mechanisms that can aect cellular response to chemotherapy, i.e. cell cycle checkpoints, DNA repair, and apoptosis (reviewed in Dougall et al., 1994; Alaoui-Jamali et al., 1997) . Several synthetic compounds such as benzoquinoid ansamycin antibiotics like herbimycin A and geldanamycin, have been used to selectively inhibit the tyrosine kinase activity associated with the erbB receptors. The benzoquinoid analog, CP127,374, has previously been shown to promote erbB-2 degradation in breast cancer cell lines expressing erbB-2 . In this study, we have examined the eect of erbB-2 depletion, DNA repair, and apoptosis using a panel of NSCLC with low versus high constitutive expression levels of the erbB receptors. Our results indicate that depletion of erbB-2 by CP127,374 can be achieved at nanomolar concentrations. Depletion of erbB-2 resulted in a concomitant inhibition of DNA repair and cell cycle arrest at G1 and promoted cisplatin-induced apoptosis. Table 1 summarizes the erbB status of lung cancer cell lines used in this study, as determined by immunoprecipitation and Western blot analysis. The erbB receptors are expressed at variable levels in the dierent cell lines. Based on the level of erbB-2 expression, cell lines used can be divided in two groups: high erbB-2 (H322, H661, H358, MGH24, SKLU1 and B2BE6) and low erbB-2 (H460, H520, MGH4, H23, H125 and B2BN1). The expression of other members of the erbB family vary from low, to high expression levels. Cells that overexpress erbB-2 also have a high level of erbB-2 phosphorylated tyrosine residues, as determined by immunoprecipitation of erbB-2 followed by Western blot with antiphosphotyrosine antibody (Table 1) . Figure 1 shows the eect of CP127,374 on NSCLC cell proliferation. Cells with high erbB-2 expression ( Figure 1a ) are more resistant to CP127,374 compared to cells with low erbB-2 (Figure 1b is approximately ®vefold more resistant to CP127,374 than H23 (IC 50 =11+0.6 nM). However, resistance to CP127,374 cannot be attributed to erbB-2 overexpression alone, unlike cisplatin, since B2BE6 transfected with erbB-2 and their neomycin-transfected controls (B2BN1) were equisensitive to CP127,374 ( Figure 1c) . In all cell lines tested, high concentrations of CP127,374 (420 nM) has only a cytostatic eect, which was reversed after removal of CP127,374.
Results
In order to examine the eect of CP127,374 on the erbB receptors, we have focused on two selected Phosphotyrosine level was determined by immunoprecipitation with polyclonal anti-erbB2 and immunoblotting using anti-phosphotyrosine monclonal antibody, 4G10, as described in Materials and methods Figure 1 Antiproliferative eect of CP127,374 on cells with low versus high erbB-2 expression. Cytotoxicity of CP127,374 was determined on NSCLC cells with high (a) versus low (b) erbB-2 expression and on bronchial cells transfected with the erbB-2 gene (c). Cells were treated continuously with the tyrosine kinase inhibitor, CP127,374, and survival was evaluated 96 h later, as described in Materials and methods NSCLC cell lines with high erbB-2 expression and constitutive autophosphorylation of tyrosine residues, H322 and H661. In H322, concentrations of 20 ± 50 nM were sucient to completely deplete erbB-2 ( Figure  2a ). These concentrations did not aect cell viability, as determined by the trypan blue staining. In H661, a concentration of at least 200 nM was required to deplete erbB-2 (Figure 2a ). ErbB-2 depletion by CP127,374 was associated with inhibition of receptor tyrosine phosphorylation (Figure 2b ). In H322, treatment with CP127,374 at concentrations required to deplete erbB-2 (20 ± 50 nM) did not aect the expression levels of erbB-3 or erbB-4 proteins while EGFR was slightly aected at the highest concentration of 50 nM, as determined by Western blot analysis (Figure 3) . Similar results were obtained with H661 using CP127,374 at a concentration of 200 nM (not shown). Figure 4 shows that treatment of H322 with CP127,374 at concentrations which deplete erbB-2 and abolishes tyrosine phosphorylation, inhibited the capacity of cells to restore the reporter gene activity of a platinated pRSV-CAT plasmid (Figure 4b ± c), thus re¯ecting downregulation of DNA repair mechanisms. As shown in Figure 4b , this inhibitory eect was modest when pRSV-CAT plasmid bore a low level of DNA damage (treatment with 2.5 mM cisplatin induces approximately 2 ± 5 adducts per kilobase of plasmid), while a strong inhibition ( Figure 4c ) was observed when the plasmid was pretreated with 5 mM cisplatin (corresponding to approximately 13 adducts per kilobase of plasmid). The inhibition of cell capacity to reactivate platinated plasmid cannot be attributed to a possible inhibition of general transcription machinery or a non-speci®c chemical challenge following CP127,374 treatment Figure 2 Eect of CP127,374 on the expression and phosphorylation of erbB-2 in H322 and H661 cell lines with high erbB-2 expression. In (a) cells were treated with varying concentrations of CP127,374 for 8 h and extracts were collected for Western blot analysis using anti-erbB-2 antibody, as described in Materials and methods. In (b) cells were serum starved for 24 h, and then treated with CP127,374 for an additional 8 h in serum-free medium. Total protein extracts from untreated and CP127,374-treated cells were subjected to immunoprecipitation with antierbB-2 antibody, and immunoprecipitates were used for Western blot analysis using anti-phosphotyrosine, as described in Materials and methods Figure 3 Eect of CP127,374 on the expression of EGFR, erbB-3 and erbB-4 in H322 cells. Cells were treated with CP127,374 for 8 h and protein extracts were immunoblotted using the appropriate anti-erbB antibody, as described in Materials and methods. Blots were then stripped and reprobed with anti-GAPDH antibody because: (i) the CAT activity of unplatinated pRSV-CAT (Figure 4a ), and galactosidase activity of pRSVb-gal (not shown) transfected plasmids were not aected by CP127,374 even at a higher concentration of 100 nM CP127,374; and (ii) cisplatin-DNA adducts in pRSV-CAT plasmid were introduced prior to cell transfection. Additionally, both trypan blue staining and TUNEL assay did not reveal any cellular death as a result of CP127,374 treatment. Exposure of H322 cells to other signaling inhibitors such the MEK inhibitor PD098059 or the p38 inhibitor SB203580 did not result in DNA repair inhibition of platinated pRSV-CAT (not shown). Inhibition of DNA repair following CP127,374 treatment was also determined using the unscheduled DNA synthesis assay (UDS, Table 2 ). Treatment with 50 nM CP127,374 did not result in any signi®cant induction of UDS. Compared to untreated cells, treatment with the DNA damaging agent, cisplatin, which triggers DNA nucleotide excision repair, induced the UDS to 217 and 320% when cells were exposed for 10 or 30 mM cisplatin for 3 h, respectively, and then cultured in cisplatin-free medium for an additional 6 h. Depletion of erbB-2 with CP127,374 resulted in 42 and 51% inhibition of UDS in comparison to cisplatin alone, when cells were exposed to 10 or 30 mM cisplatin, respectively (Table 2 ). In H661, 50% DNA repair inhibition, using both the host cell reactivation and UDS, was obtained with a CP127,374 concentration of 200 nM (not shown).
As indicated in Figure 5 , CP127,374 concentrations required to deplete erbB-2 in H322 induces accumulation of cells at the G1 phase of the cell cycle and a reduction of the proportion of cells in S phase ( Figure   Figure 4 Eect of CP127,374 on DNA repair capacity in intact cells as determined by the host cell reactivation assay. H322 cells were transfected with (a) undamaged pRSV-CAT control vector, (b) pRSV-CAT pretreated with 2.5 mM cisplatin, or (c) pRSV-CAT pretreated with 5 mM cisplatin. Cells were then exposed continuously to 50 nM CP127,374, and then collected 48 h after transfection for CAT activity measurement 5b ± c). The percentage of cells in G2/M was not aected by CP127,374 treatment. G1 arrest following CP127,374 treatment was not associated with induction of p53 or p21/WAF1/CIP1 proteins in both the H322 and H661 cells (both of which express mutated p53, not shown). Figure 6 shows the cellular response to cisplatin, in the absence and presence of CP127,374. Cells constitutively overexpressing erbB-2 or cells transfected with erbB-2 were 5-to 16-fold more resistant to cisplatin-induced toxicity and apoptosis compared to cells with low expression of erbB-2 (Figure 6a) . A nontoxic dose of CP127,374 (1 nM) had no signi®cant eect on cisplatin toxicity, both in low and high erbB-2-expressing cells (Figure 6b ± c) . High concentrations of CP127,374 (10 to 450 nM) have only a cytostatic eect on cell growth. A combination of CP127,374 and cisplatin led to an irreversible growth inhibition even at low cisplatin concentrations (Figure 6b ± c) . This synergistic activity was not due to changes in cisplatin accumulation in presence of CP127,374 (treatment of H322 cells with 30 mM cisplatin for 3 h resulted in 187+29 and 210+37 pmol cisplatin/mg total protein, in the absence and presence of 50 nM CP127,374, respectively, as determined by atomic absorption spectrometry). Figure 7 shows the eect of CP127,374 on the induction of apoptosis in H322 cells using the TUNEL assay. The proportion of apoptotic cells was negligible at CP127,374 concentrations required to deplete erbB-2. Interestingly, erbB-2 depletion with CP127,374 potentiates cisplatin-induced apoptosis (Figure 7 ). Cotreatment with 10 nM CP127,374 and 10 mM cisplatin induced approximately 18% apoptosis compared to approximately 2% when cells were treated with cisplatin alone. Cotreatment with 50 nM CP127,374 and 25 mM cisplatin induced approximately 81% apoptosis compared to 41% when cells were treated with cisplatin alone.
Discussion
Regulation of erbB tyrosine kinase receptor activity is mediated by receptor homodimerization as well as by speci®c inter-receptor heterodimerization between the epidermal growth factor receptor (EGFR), erbB-2, erbB-3 and erbB-4 (Carraway and Cantly 1994; Karunagaran et al., 1995; Earp, 1995; Graus-Porta et al., 1995; Riese et al., 1995; Tzahar et al., 1996; PinkasKramarski et al., 1996a,b; Lewis et al., 1996) . Activation of erbB-2 results in receptor trans-autophosphorylation and activation of its intrinsic tyrosine kinase activity, leading to the activation of multiple signaling cascades (reviewed in Dougall et al., 1994) .
Overexpression of erbB-2 has been associated with a poor response to anticancer drugs in a variety of cancers including NSCLC (Kern et al., 1990; Tsai et al., 1993) . In this study, we have used NSCLC cells constitutively overexpressing erbB-2 to examine the relationship between erbB-2 depletion, DNA repair capacity, and apoptosis. Depletion of erbB-2 was Cells in which semiconservative DNA synthesis was completely blocked were treated with 50 nM CP127,374 for 8 h. Medium was then replaced with fresh serum-free medium containing 10 or 30 mM cisplatin and 3 H-dThd. After 3 h, cisplatin treatment was stopped by washing cells twice with PBS, and then replaced with fresh medium and 3 H-dThd for 6 h. Cells were then collected and the incorporation of 3 H-dThd was determined as described in Materials and methods Figure 5 Eect of CP127,374 on cell cycle distribution in H322. H322 cells were treated for 48 h with solvent alone (a), 50 nM (b) or 100 nM (c) concentrations of CP127,374 to deplete erbB-2, then ®xed, stained with propidium iodide, and subjected to cell cycle analysis achieved using the benzoquinoid analog CP127,374. This class of compounds has been shown to promote the degradation of erbB receptors and inhibit tyrosine kinase activity by a mechanism involving disruption of the erbB-2/glucose regulated protein GRP94 (Chavany et al., 1996) or erbB-2/ HSP90 (Stebbins et al., 1997) complex. Our results indicate that nanomolar concentrations of CP127,374 strongly depletes the level of erbB-2 in NSCLC cells, in agreement with previous studies on breast cancer cell lines . This depletion was shown to be selective for erbB-2, compared to EGFR, erbB-3 or erbB-4 proteins.
CP127,374-mediated erbB-2 depletion was associated with a strong inhibition of the capacity to repair cisplatin-induced DNA damage in intact cells, as determined by two independent assays: the host cell reactivation and unscheduled DNA synthesis (UDS). This inhibition of DNA repair following erbB-2 depletion supports previous results using speci®c antibodies directed against erbB-2 ( Arteaga et al., 1994; Pietras et al., 1994; Yen et al., 1997) . While the Figure 6 Cytotoxic eect of cisplatin, in the absence and presence of CP127,374. A panel of cell lines expressing high erbB-2 (H322, H661, H358, MGH 24 and B2BE6) or low erbB-2 (H460, H520, MGH4 and B2BN1) were treated with either cisplatin alone (a) or a combination of cisplatin and CP127,374 (b ± c) at the concentrations indicated. The cytotoxicity of these treatments was measured as described in Materials and methods UDS assay cannot rule out an eect of CP127,374 on distribution of cisplatin in various cell compartments, the host cell reactivation assay does suggest that this may not be the case, since damage to the plasmid DNA was induced prior to transfection.
DNA repair is known to be coupled to cell cycle checkpoint mechanisms (Hartwell and Kastan, 1994; El-Deiry et al., 1994) , and a number of DNA repair proteins such as RPA, PCNA, p53, and the TFIIH transcription-repair complex are also involved in cell cycle regulation Leveillard et al., 1996; Warbrick et al., 1997) . Furthermore, alterations in cell cycle checkpoint and/or DNA repair mechanisms can lead to drug resistance (St. Croix et al., 1996; Chaney and Sancer, 1996) . ErbB-2 depletion by CP127,374 was associated with cell accumulation at the G1 phase of the cell cycle. Both H322 and H661 cell lines used in this study express mutated p53 and Western blot analysis revealed a lack of induction of p53 or p21/WAF1/CIP1 protein following CP127,374 treatment. Furthermore, G1 arrest was also observed in the H358 cell line, which is p53-de®cient (not shown). Together, these data suggest that CP127,374-induced G1 arrest is independent of p53-regulated mechanisms. This does not exclude induction of other inhibitors of cyclin-dependent kinases, since G1 arrest following treatment of cancer cells with the tyrosine kinase inhibitor herbimycin, or antibodies against EGFR, was found to be associated with an increase expression of the cell cycle inhibitor p27 KIP1 , but not p21/WAF1/CIP1 (Deng et al., 1996; Wu et al., 1996) .
Both the erbB ligand, heregulin, and antibodies against erbB-2 were found to induce cell cycle delay (Bacus et al., 1996) . Defective DNA repair was observed in the G1-defective cells, which was attributed to altered cycle checkpoint mechanisms (Deng et al., 1995) . Expression of p21 in p21 7/7 cells increased the proportion of cells in G1 phase (Serrano et al., 1995) and restored DNA repair capacity (MacDonald et al., 1996) . While the molecular mechanisms by which CP127,374 led to G1 arrest and its relationship to downregulation of DNA repair in NSCLC cells remain to be determined, our data suggests that DNA repair inhibition may be independent of G1 cell cycle arrest since DNA repair downregulation by CP127,374 was observed using the unscheduled DNA synthesis assay, where cells were arrested at G0 phase of the cell cycle.
There is evidence that downregulation of DNA repair can trigger apoptosis mechanisms (Ford et al., 1998; Vreeswjk et al., 1998) . Our study indicates that exposure to CP127,374 alone at concentrations required to deplete erbB-2, resulted in negligible apoptosis, while DNA repair was signi®cantly inhibited. A combination of CP127,374 and cisplatin strongly potentiated cisplatin-induced apoptosis. More interestingly, potentiation of cisplatin-induced apoptosis with CP127,374 was observed in cells with mutated p53, which is a common alteration in NSCLC, supporting a p53-independent mechanism. It is likely that downregulation of DNA repair by CP127,374, as a result of erbB depletion, may favor apoptotic signals following exposure to external stress such as treatment Figure 7 Eect of CP127,374 on the induction of apoptosis in H322 cells using the TUNEL assay. Nonspeci®c¯uorescence was measured using ®xed and permeabilized cells and incubated in label solution without terminal transferase, as described in Materials and methods. Histograms of relative log¯uorescence represent 9000 to 14 000 events counted for each condition with cisplatin. This is supported by the fact that inhibition of DNA repair of damage induced by cisplatin can be detected as early as 10 h posttreatment. In contrast, apoptosis induced by cisplatin alone or in combination with CP127,374 was observed only after at least 48 h post-treatment, suggesting that apoptotic signals may be secondary to DNA repair downregulation.
We have previously shown that DNA repair is regulated by a ras-dependent pathway . The H322 cell line used in this study has a wild type ras. The ras protein has also been reported to be involved in the regulation of cyclin D1 and the CDK inhibitor, p27 KIP1 (Aktas et al., 1997) . Pathways downsteam of ras are involved in cellular responses to stress. The activities of JNK and p38, two components downstream of ras, increase in parallel with apoptosis in NGF-deprived PC12 cells, and blockade of JNK or p38 blocks apoptosis in PC12 (Xia et al., 1995) . SAPK was implicated in growth arrest and apoptosis (Xia et al., 1995) and blockade of SAPK was shown to confer resistance to cisplatininduced apoptosis (Zanke et al., 1996) . The absence of DNA repair inhibition by the p38 inhibitor, SB203580 and the MEK inhibitor PD098059 suggest that other signaling components are involved. A recent study has reported that inhibition of the Jun kinase/stressactivated protein kinase (JNK/SAPK) resulted in inhibition of DNA repair and enhanced sensitivity to cisplatin (Potapova et al., 1997) , suggesting that this pathway may play a role in the regulation of DNA repair.
In summary, this study supports a pivotal role of erbB receptor signaling in the coregulation of DNA repair, cell cycle checkpoints, and apoptosis; all are important cellular defence mechanisms that determine cell destiny following DNA damage.
Materials and methods

Chemicals and reagents
CP127,374 was kindly provided by Dr J Moyer (Central Research Division, P®zer Inc., Groton, CT). Cisplatin was obtained from the Pharmacy of the Sir Mortimer B Davis Jewish General Hospital. Escherichia coli chloramphenicol acetyltransferase and acetyl coenzyme A were obtained from Pharmacia Biotech (Baie D'UrfeÂ , Quebec). D-threo-[dichloroacetyl-1-14 C] chloramphenicol (SA 53.1 mCi/ mmol) was obtained from Amersham (Oakville, Ontario). Tritiated-thymidine ( 3 H-dThd, SA 20 Ci/mmol) was obtained from Dupont-NEN, Mississauga, Ontario. Cisplatin was dissolved in water and CP127,374 was dissolved in DMSO at a ®nal concentration of less than 0.05% in culture medium.
Cell culture
The cell lines used in this study are described in Table 1 . All cells with the exception of bronchial cells, MGH4 and MGH24, were obtained from the ATCC and were maintained in the corresponding media according to the American Type Culture Collection (ATCC) guidelines. (ATCC cell lines & Hybridomas, 7th edition, 1992) . MGH4 and MGH24 were obtained from Dr M-S Tsao (Liu and Tsao, 1993) . Simian virus 40 large T-antigen immortalized human normal bronchial cells transfected with neomycin gene (B2BN1), or the wild type human erbB-2 gene (B2BE6) were provided by Dr BI Gerwin (Noguchi et al., 1993) . These cells were maintained in medium for normal human bronchial cells (BEGM BulletKit, Clonetics Corporation; CC-3170). All cells were maintained in an atmosphere of 5% CO 2 .
Cytotoxicity
Exponentially growing cells (1 ± 3610 3 cells/well) were seeded in 96 well plates and incubated for 16 h. Cells were treated continuously with the tyrosine kinase inhibitor CP127,374 or cisplatin. For drug combination experiments, cells were treated for 16 h with CP127,374 followed by addition of cisplatin. Cell survival was evaluated 96 h later, by replacing the culture media with 150 ml fresh medium containing 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buer, pH 7.4. Fifty ml of 2.5 mg/ml of 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, St Louis, MO) in phosphate buer solution (PBS), pH 7.4, were then added. After 4 h of incubation at 378C, the medium and MTT were removed and 200 ml of DMSO were added to dissolve the precipitate of reduced MTT, followed by addition of 25 ml glycine buer (0.1 M glycine plus 0.1 M NaCl, pH 10.5). Plates were then shaken for 15 min and the absorbance was determined at 570 nM with a microplate reader (BIORAD, model 450). The IC 50 was calculated as the dose of drug causing a 50% inhibition in the absorbance as compared to untreated cells.
Western blot analysis
Cells were grown in serum supplemented medium until 70% con¯uence in 75 cm 2¯a sks. Cells were then treated with CP127,374 for 8 h. Medium was removed and cells were washed twice in cold PBS, then lysed directly using lysis buer (1% Triton X-100, 10 mM Tris-HCl pH 8.0, 60 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5% NP-40, 0.5 mM phenylmethylsulfonyl¯uoride, 0.01 mg/ml leupeptin, 0.01 mg/ml pepstatin, and 0.01 mg/ml aprotonin, 5 mM sodium orthovanadate, 10 mM sodium PPi). The lysate was incubated for 10 ± 15 min at 48C and then centrifuged at 14 000 g at 48C for 15 min. The supernatant was used to determine protein concentration. Cell extracts were resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose (Costar, Cambridge, MA), blocked in 5% milk in PBS, then incubated with either monoclonal antibody against erbB-2 (Ab-3, clone 3B5; Oncogene Science, Cambridge, MA), polyclonal anti-EGFR (Ab-4, clone 455, Oncogene Science), polyclonal anti-erbB-3 (clone C-17, Santa Cruz Biotechnology, Santa Cruz, CA), or polyclonal anti-erbB-4 (clone C-18, Santa Cruz). Enhanced chemiluminescence detection was performed using ECL detection reagents (Amersham). Blots were subsequently stripped in 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7, 508C for 30 min, then immunoblotted with monoclonal anti-GAPDH (clone 6C5, Cedarlane Laboratories, Ontario).
Immunoprecipitation
For immunoprecipitation, 100 mg of protein were immunoprecipitated with the antibodies indicated (polyclonal anti-erbB-2, clone C-18, Santa Cruz Biotechnology, Santa Cruz, CA; monoclonal anti-erbB-3, clone RTJ.2, Santa Cruz Biotechnology; monoclonal anti-erbB-4, clone H4.77, Neomarkers; monoclonal anti-EGFR, clone EGFR1, Amersham Life Sciences, Oakville, Ontario). Samples were then resuspended with protein-A/protein-G agarose (Pharmacia Biotech, Baie D'Urfe, Quebec) and incubated with gentle agitation for overnight at 48C. The beads were isolated by centrifugation at 2000 g for 1 min. The immunoprecipitates were then washed four times in cold PBS containing 0.1% Tween-20, resuspended in SDS sample buer, boiled for 5 min and pelleted by centrifugation at 2000 g for 1 min. The eluate was loaded onto a 7.5% SDS-polyacrylamide gel, transferred to nitrocellulose (Costar, Cambridge, MA, USA), blocked overnight in PBS containing 3% dried milk, then incubated with polyclonal antibody against EGFR (Brown et al., 1994) , erbB-2 (C-18, Santa Cruz Biotechnology), erbB-3 (C-17, Santa Cruz Biotechnology), or erbB-4 (C-18, Santa Cruz Bio-technology), or monoclonal anti-phosphotyrosine (clone 4G10, Upstate Biotechnology Inc., NY, USA). Blots were developed using the alkaline phosphatase substrate detection kit from Vector Laboratories (Burlingame, CA, USA).
Cell cycle analysis
Cells were treated with CP127,374 for 48 h in serumcontaining medium. Cells were washed twice with PBS, collected after treatment with trypsin, then washed with PBS, and ®xed in 70% ethanol diluted in PBS. Fixed cells were washed three times with PBS and resuspended at a density of 2 ± 5610 6 cells/ml, in a solution of PBS containing 522 mg/l Spermine THC (Sigma), 0.5 mM Tris pH 8.0, 35 mg/ml RNase A and 50 mg/ml propidium iodide. FACS analysis was performed on an Epics-Pro®le II¯ow cytometer and cell cycle distribution was determined using the Multicycle program (Pheonix Flow Systems).
Apoptosis assay
Cells were seeded at 1610 6 cells per 75 cm 2 plate, then left to attach overnight. The cells were then exposed to media alone, cisplatin, or CP127,374 continuously for 72 h. Cells were collected and then diluted to 1610 6 /100 ml PBS in 96 well plates for the terminal deoxynucleotidyl transferasemediated UTP nick end labeling (TUNEL) assay. Cells were ®xed using 200 ml of 70% ethanol with gentle shaking at 48C for 30 min. Cells were then washed with PBS, and permeabilized with 1% Triton X-100 in 0.1% sodium citrate on ice for 2 min. Cells were washed twice with PBS, then labeled with 50 ml/well of the In Situ Cell Death Detection kit TUNEL reaction mixture (Boehringer Mannheim, Laval, Quebec) at 378C in the dark for 1 h. Cells were then washed three times with 1% BSA in PBS and resuspended in 500 ml PBS for analysis by¯ow cytometry using an Epics-Pro®le II¯ow cytometer.
DNA repair assays
DNA repair capacity in intact cells was estimated using the host cell reactivation assay and unscheduled DNA synthesis (UDS) assay. In the host cell reactivation assay (HCR), the pRSV-CAT plasmid (ATCC) was used to estimate the capacity of cells to reactivate cisplatindamaged plasmid. Plasmid treatment and preparation were carried out as described (Wood et al., 1995; ZengRong et al., 1995) . The pRSV-b-gal plasmid, which contains the b-galactosidase gene driven by the RSV promoter, was used as internal control for transfection eciency (Zeng-Rong et al., 1995) . Cells were cultured in 6-well plates and transfected with 3 mg of pRSV-CAT plasmid and 2 mg of pRSV-b-gal plasmid per well using LipofectAMINE reagent (Gibco/BRL, Burlington, Ontario) as per manufacturer's instructions. After 5 h, cells were incubated in fresh medium containing 50 nM CP127,374. Cells were collected 48 h after transfection and cell extracts were used to determine CAT and b-galactosidase activity as described previously (Zeng-Rong et al., 1995) . Relative CAT activity was expressed as % CAT conversion/50 mg of total protein extract. For the unscheduled DNA synthesis (UDS) assay, cells were seeded at 1610 6 cells per well in 6-well plates and kept undisturbed until full con¯uence in medium containing 0.05 mCi/ml [ 14 C]-thymidine (used as an internal control to normalize for cell number). Cells were then washed twice with PBS and medium was substituted for arginine-free medium (MEM Select-Amine 1 , Gibco/ BRL) containing 1% serum and 0.05 mCi/ml [ 14 C]-thymidine for an additional 48 h. The radioactivity was then chased by an additional 2 h incubation in medium containing 10 75 M cold thymidine. Cells were washed twice with serum-free medium and then treated with CP127,374 (50 nM), cisplatin (10 or 30 mM) or CP127,374 and cisplatin in the presence of 10 mCi/ml 3 H-dThd. In the combination treatments, CP127,374 was continuously included to the culture medium, and cisplatin was added 8 h after CP127,374 treatment was initiated. This timing was based on Western blot analysis indicating that depletion of erbB-2 requires approximately 8 h incubation with CP127,374. Cisplatin treatment was stopped after 3 h. Cells were then washed twice with PBS and further cultured in fresh arginine-free medium containing 1% serum and 10 mCi/ml 3 H-dThd for an additional 6 h. The doubly-labeled cells were collected using trypsin-EDTA, washed twice with PBS and deposited on polycarbonate (PC) ®lters (2.0 mm, 25 mm, Nucleopore) using 25 mm Swinnex (Millipore Canada Ltd., Mississauga, Ontario). Cells were lysed for 45 min with 2% SDS and 0.025 M EDTA (pH 7.9). Filters were then washed two times with 3 ml 0.02 M EDTA (pH 7.9). Next, the ®lters were dried and the ratio 3 HdThd/ 14 C-dThd was determined using a Wallac-Liquid Scintillator Counter. Results were corrected to d.p.m. and are expressed as % incorporation in drug-treated cells compared to the incorporation in control cells treated with solvent alone (0.05% DMSO).
